论文部分内容阅读
[目的]观察健脾理气方对HepG2人肝癌细胞株p53和bcl-2基因表达的影响。[方法]30只雄性SD大鼠随机分为健脾理气方(中药)组、0.85%氯化钠(对照)组和顺铂(化疗)组,每组10只。利用血清药理学方法制备药物血清,3组分别加入PRMI 1640血清培养的HepG2人肝癌细胞株中,作用48 h。应用免疫细胞化学方法和图像分析方法观察健脾理气方对HepG2人肝癌细胞株p53、bcl-2基因表达影响。[结果]①免疫细胞化学法显示抑癌基因p53主要定位在细胞核,癌基因bcl-2主要定位在细胞质内。药物血清作用后,p53表达明显增强;bcl-2表达明显降低。随着作用时间延长,2种基因表达改变更明显。②中药组与对照组p53和bcl-2光度(AOD)值差异有统计学意义(P<0.01)。③化疗组作用结果与中药组相似。[结论]健脾理气方药物血清上调p53、下调bcl-2,达到抑制HepG2人肝癌细胞株的作用。为应用健脾理气方治疗肝癌提供实验依据。
[Objective] To observe the effect of Jianpi Liqi prescription on the gene expression of p53 and bcl-2 in HepG2 human hepatoma cell line. [Methods] Thirty male Sprague - Dawley rats were randomly divided into Jianpi Liqi (TCM) group, 0.85% sodium chloride (control) group and cisplatin (chemotherapy) group, with 10 rats in each group. Serum pharmacological methods were used to prepare drug serum, and three groups were added to HepG2 human hepatoma cell line cultured in PRMI 1640 serum for 48 hours. Immunocytochemistry and image analysis were used to observe the effect of Jianpi Liqi prescription on the gene expression of p53 and bcl-2 in HepG2 human hepatoma cell line. [Results] ① Immunocytochemistry showed that the tumor suppressor gene p53 mainly located in the nucleus and the oncogene bcl-2 mainly located in the cytoplasm. After the effect of drug serum, the expression of p53 increased obviously; the expression of bcl-2 decreased obviously. With the extension of time, two kinds of gene expression changes more pronounced. ② The difference of AOD value of p53 and bcl-2 between the traditional Chinese medicine group and the control group was statistically significant (P <0.01). The results of chemotherapy group is similar to that of traditional Chinese medicine group. [Conclusion] Jianpi Liqi prescription serum upregulates p53, down-regulates bcl-2, and achieves the effect of inhibiting HepG2 human hepatoma cell line. For the application of spleen Qi prescription liver cancer experimental basis.